<DOC>
	<DOCNO>NCT00569140</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerability , pharmacokinetic profile E10030 intravitreous injection administer monotherapy combination LucentisÂ® 0.5 mg/eye subject subfoveal choroidal neovascularization secondary age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>A Phase 1 , Safety , Tolerability Pharmacokinetic Profile Intravitreous Injections E10030 ( Anti-PDGF Pegylated Aptamer ) Subjects With Neovascular Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Subfoveal choroidal neovascularization ( CNV ) due AMD Any follow underlying disease include : Diabetic retinopathy . History evidence severe cardiac disease ( e.g. , NYHA Functional Class III IV see Appendix 19.6 ) , history clinical evidence unstable angina , acute coronary syndrome , myocardial infarction revascularization 6 month , ventricular tachyarrythmias require ongoing treatment . History evidence clinically significant peripheral vascular disease , intermittent claudication prior amputation . Clinically significant impaired renal ( serum creatinine &gt; 2.5 mg/dl s/p renal transplant receive dialysis ) hepatic function . Stroke ( within 12 month trial entry ) . Any major surgical procedure within one month trial entry . Previous therapeutic radiation region study eye . Any treatment investigational agent past 60 day condition . Known serious allergy fluorescein dye use angiography , component ranibizumab formulation , component E10030 formulation .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>